RU2020130048A - Модуляторы sting (стимулятора генов интерферона) на основе циклопентана - Google Patents

Модуляторы sting (стимулятора генов интерферона) на основе циклопентана Download PDF

Info

Publication number
RU2020130048A
RU2020130048A RU2020130048A RU2020130048A RU2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A
Authority
RU
Russia
Prior art keywords
compound
salt according
salt
pharmaceutically acceptable
hydrogen
Prior art date
Application number
RU2020130048A
Other languages
English (en)
Russian (ru)
Other versions
RU2020130048A3 (cg-RX-API-DMAC7.html
Inventor
Мартин Джеймс Уайтс
Индраван Джеймс Макалпайн
Райан ПЭТМАН
Юджин Яньцзинь ЖУЙ
Эндрю Фенсом
Андреас Мадерна
Мехран ДЖАЛЭЙ
Кетан С. Гадживала
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2020130048A publication Critical patent/RU2020130048A/ru
Publication of RU2020130048A3 publication Critical patent/RU2020130048A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2020130048A 2018-03-15 2019-03-12 Модуляторы sting (стимулятора генов интерферона) на основе циклопентана RU2020130048A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US62/643,467 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US62/666,204 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US62/742,532 2018-10-08
US201962809990P 2019-02-25 2019-02-25
US62/809,990 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (2)

Publication Number Publication Date
RU2020130048A true RU2020130048A (ru) 2022-04-15
RU2020130048A3 RU2020130048A3 (cg-RX-API-DMAC7.html) 2022-04-15

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020130048A RU2020130048A (ru) 2018-03-15 2019-03-12 Модуляторы sting (стимулятора генов интерферона) на основе циклопентана

Country Status (25)

Country Link
US (4) US10538542B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765474B1 (cg-RX-API-DMAC7.html)
JP (1) JP7266942B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200131878A (cg-RX-API-DMAC7.html)
CN (1) CN111918871A (cg-RX-API-DMAC7.html)
AU (1) AU2019234043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093631C (cg-RX-API-DMAC7.html)
CL (1) CL2020002352A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200382A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000160A (cg-RX-API-DMAC7.html)
EC (1) ECSP20057847A (cg-RX-API-DMAC7.html)
ES (1) ES2923298T3 (cg-RX-API-DMAC7.html)
IL (1) IL277278A (cg-RX-API-DMAC7.html)
MA (1) MA52012A (cg-RX-API-DMAC7.html)
MX (1) MX2020009587A (cg-RX-API-DMAC7.html)
NI (1) NI202000058A (cg-RX-API-DMAC7.html)
PE (1) PE20210412A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551486A1 (cg-RX-API-DMAC7.html)
PY (1) PY1919127A (cg-RX-API-DMAC7.html)
RU (1) RU2020130048A (cg-RX-API-DMAC7.html)
SG (1) SG11202008102VA (cg-RX-API-DMAC7.html)
TW (1) TWI741268B (cg-RX-API-DMAC7.html)
UY (1) UY38145A (cg-RX-API-DMAC7.html)
WO (1) WO2019175776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
PH12022550709A1 (en) * 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4259642A1 (en) * 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
ECSP20057847A (es) 2021-04-29
KR20200131878A (ko) 2020-11-24
PE20210412A1 (es) 2021-03-04
WO2019175776A1 (en) 2019-09-19
CR20200382A (es) 2020-12-10
JP7266942B2 (ja) 2023-05-01
US10538542B2 (en) 2020-01-21
MX2020009587A (es) 2020-10-05
EP3765474A1 (en) 2021-01-20
US10968242B2 (en) 2021-04-06
PH12020551486A1 (en) 2021-08-23
US20190284216A1 (en) 2019-09-19
PY1919127A (es) 2020-08-26
CA3093631A1 (en) 2019-09-19
CA3093631C (en) 2023-01-24
ES2923298T3 (es) 2022-09-26
CN111918871A (zh) 2020-11-10
TWI741268B (zh) 2021-10-01
US20200102334A1 (en) 2020-04-02
CL2020002352A1 (es) 2020-12-18
IL277278A (en) 2020-10-29
MA52012A (fr) 2021-01-20
NI202000058A (es) 2021-01-08
BR112020018593A2 (pt) 2020-12-29
AU2019234043A1 (en) 2020-09-17
US20230382932A1 (en) 2023-11-30
DOP2020000160A (es) 2020-09-30
JP2021518335A (ja) 2021-08-02
SG11202008102VA (en) 2020-09-29
UY38145A (es) 2019-10-31
TW201945036A (zh) 2019-12-01
EP3765474B1 (en) 2022-06-15
RU2020130048A3 (cg-RX-API-DMAC7.html) 2022-04-15
US20210230196A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
TWI713889B (zh) 胜肽化合物之環化方法
ES2624353T3 (es) 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
JP6309590B2 (ja) フラビウィルス科ウィルス感染治療用の修飾2’および3’−ヌクレオシドプロドラッグ
ES2588596T3 (es) Moléculas de anticuerpo que se unen a IL-17A e IL-17F
Manoel-Caetano et al. Implications of genetic variability of Trypanosoma cruzi for the pathogenesis of Chagas disease
JP2023524767A5 (cg-RX-API-DMAC7.html)
EP3151920B1 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2003064621A3 (en) HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
AU2008326569A1 (en) 2',4'-substituted nucleosides as antiviral agents
CA2386404A1 (en) Method of treating inflammatory conditions with progesterone or progesterone analogs
BR0314138A (pt) composição, e, método
JP7266942B2 (ja) Sting(インターフェロン遺伝子刺激因子)のシクロペンタン-ベースのモジュレーター
DK379089A (da) Tetrahydro-1-benzoec,daaindolpropionsyre-sulfonamider, deres fremstilling og anvendelse
CY1108808T1 (el) Ενωσεις μοτιλιδης
US11040975B2 (en) Carbocyclic nucleoside reverse transcriptase inhibitors
Sumpf et al. Histone deacetylase inhibitor MS-275 augments expression of a subset of IFN-γ-regulated genes in Toxoplasma gondii-infected macrophages but does not improve parasite control
ES468918A1 (es) Procedimiento para la preparacion de complejos de peptido
Drlica et al. Roles of DNA topoisomerases in bacterial chromosome structure and function.
MX2023013017A (es) Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos.
JPS6419005A (en) Agent for promoting growth of mycelia and formation of fruit body of basidiomycetes
Kulaeva et al. Molecular mechanisms of transcription through a nucleosome by RNA polymerase II
Stephens Turnover of tubulin in ciliary outer doublet microtubules
BR0109365A (pt) Oligonucleotìdeos sintéticos como indutores da diferenciação eritróide
Kim et al. Cefoperazone (Cefobid) for treating men with gonorrhoea caused by penicillinase producing Neisseria gonorrhoeae.
CR20200615A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano